ArticleCureus2025
Verification of the Short-Term Impact of Imeglimin on Liver Fibrosis Markers Stratified by Liver Fibrosis Risk in Patients With Type 2 Diabetes.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective This study aimed to evaluate the effects of imeglimin on Fibrosis-4 index (FIB-4) and aspartate aminotransferase to platelet ratio index (APRI) across three subgroups classified according to the FIB-4 classification for assessing liver fibrosis risk in patients with type 2 diabetes mellitus (T2DM). Materials and methods Eighty-three patients with T2DM were classified into three subgroups based on their FIB-4 at the initiation of imeglimin, following the FIB-4 classification: Group 1 (G1) (FIB-4 < 1.30, n = 25), Group 2 (G2) (1.30 ≤ FIB-4 < 2.67, n = 44), and Group 3 (G3) (FIB-4 ≥ 2.67, n = 14). Then we evaluated the changes (Δ) in FIB-4 and APRI three months after the initiation of imeglimin in each subgroup. Subsequently, ΔFIB-4 and ΔAPRI were compared across the three subgroups. Baseline parameters and their changes correlated with ΔFIB-4 were also analyzed. Results FIB-4 significantly decreased in G2 (p = 0.046) and G3 (p = 0.017), while APRI showed significant reductions across all three subgroups (G1: p = 0.007, G2: p < 0.001, G3: p = 0.002). ΔFIB-4 in G3 was significantly greater than that observed in G1 (p = 0.01), and ΔAPRI in G3 was significantly greater than those in G1 (p = 0.004) and G2 (p = 0.007). ΔFIB-4 was negatively correlated with baseline FIB-4 and Triglycerides (TG), and positively correlated with Δγ-glutamyl transpeptidase (γ-GTP). Conclusions The short-term effects of imeglimin on FIB-4 and APRI in patients with T2DM may be more pronounced in patients with higher baseline FIB-4 levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.